A Study about the Liver and Kidney safety of patients taking siddha metallic drugs for long duration

Hepato-Renal safety of patients taking prolonged course of siddha metallic drugs from Noi Naadal perspective

Status

Recruiting

Phases

Phase 1

Study type

Observational

Source

CTRI

Registry ID

CTRI/2017/03/008160

Enrollment

100

Registered

2017-03-20

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Taking Siddha metallic drug preparations for 2 months and above duration for any disease and those who are not taking any allopathic medication for long duration

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1) GROUP A Patients who are taking Siddha metallic drug preparations for more than two months and above duration up to one year 2) GROUP B Patients who had taken Siddha metallic drugs for 2 months to one year duration and have not taken metallic drugs for the last one year

Exclusion criteria

Exclusion criteria: 1) In Group A Patients with hepato renal pathology 2) Presence of any major illness which affects the clinical parameters 3)Patients who are undergoing allopathic medication and have underwent alopathic medications for one month duration

Design outcomes

Primary

Measure	Time frame
Will be observed from the parameters used for assessment Both Siddha parameters and modern laboratory parametersTimepoint: 1 year	—

Secondary

Measure	Time frame
Will be observed from the parameters used for the assessment both Siddha parameters and modern diagnostic parametersTimepoint: Study duration is one year Patients who are taking metallic Siddha drug preparations for more than two months duration are included in the study	—

Countries

India

Contacts

Public ContactDr P Parvathy

National Institute of Siddha

parvathyamaldev@gmail.com9094219424

Outcome results